AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

The latest report, Panic Attack Treatment Global Market Report 2025, brings light to the rapid growth of panic attack treatment market in recent years. The market size is expected to surge from $3.04 ...

Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease ...

A study published in The BMJ compares the evidence around intermittent fasting and calorie restriction for weight loss. Prof Maik Pietzner, Chair in Health Data Modelling, Queen Mary University of ...

Genmab A/S ADS has a trailing 12 month Price to Earnings (P/E) ratio of 12.7 while the S&P 500 average is 29.3 Its forward ...

AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

AbbVie Golden Ticket Comes to a ClosePress release2025-06-18 11:48AbbVie Golden Ticket ceremony at SmiLe Venture Hub.Lund, Sweden – The one-year AbbVie Golden Ticket program has officially concluded – ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...